TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26389646

Group type: EXPERIMENTAL
Intervention: Operant conditioning of eye gaze toward happy faces (train-happy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Operant conditioning of eye gaze toward neutral faces (train-neutral)
Number of subjects: 32
Study: 24847084

Group type: EXPERIMENTAL
Intervention: Online spaced-education (SE) game; 87% completion rate (48/55 clinicians).
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group received identical educational content in an online posting; 84% reading rate (47/56 clinicians).
Number of subjects: 111
Study: 22397987

Group type: EXPERIMENTAL
Intervention: Leg wound drain (size 10 high vacuum, 20 kPa)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No leg wound drain
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Leg wound drain
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 20552088

Group type: EXPERIMENTAL
Intervention: Nonsubmerged healing
Number of subjects: 29

Group type: COMPARATOR
Intervention: Submerged healing
Number of subjects: 29
Study: 18783114

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with an infrared laser (830nm, 500mW, 20s, 4J/point), once a week for four consecutive weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment, once a week for four consecutive weeks.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 15599360

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation (10 Hz, 250 mJ input, 112 mJ output) with liquid adhesive (Super Bonder and Single Bond adhesive)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 17% EDTA with liquid adhesive (Super Bonder and Single Bond adhesive)
Number of subjects: 94
Study: 11855313

Group type: EXPERIMENTAL
Intervention: Amlodipine (norvask)
Number of subjects: 18
Study: 10442192

Group type: EXPERIMENTAL
Intervention: Cisplatin with amifostine (740 mg/m2)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cisplatin only (70 mg/m2)
Number of subjects: 74
Study: 7872933

Group type: EXPERIMENTAL
Intervention: Padua Inventory (PI)
Number of subjects: 858
Study: 2240628

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) added to isoflurane anesthesia (50%-60%)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Isoflurane anesthesia without N2O
Number of subjects: 26
Study: 15297

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg t.i.d.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30939592

Group type: EXPERIMENTAL
Intervention: d-methadone (single doses up to 150 mg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: d-methadone (daily doses up to 75 mg for 10 days)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: d-methadone (higher dose levels)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: d-methadone (various doses)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: d-methadone (higher doses)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: d-methadone (60 mg or above)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: d-methadone
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 28515098

Group type: EXPERIMENTAL
Intervention: Procollagen type III N‐terminal propeptide (PIIINP)
Number of subjects: 3068

Group type: EXPERIMENTAL
Intervention: Collagen type I carboxy-terminal telopeptide (ICTP)
Number of subjects: 3068
Study: 25607118

Group type: EXPERIMENTAL
Intervention: LifeWave Energy Enhancer (LEE) patches
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 20
Study: 23506291

Group type: EXPERIMENTAL
Intervention: Peach pulp
Number of subjects: 57

Group type: COMPARATOR
Intervention: Peach peel
Number of subjects: 57

Group type: COMPARATOR
Intervention: Peach lipid transfer protein (LTP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Profilin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Serum-specific IgE to peach
Number of subjects: 57

Group type: COMPARATOR
Intervention: rPru p 3-specific IgE
Number of subjects: 57

Group type: COMPARATOR
Intervention: rPru p 1-specific IgE
Number of subjects: 57

Group type: COMPARATOR
Intervention: rPru p 4-specific IgE
Number of subjects: 57
Study: 21681064

Group type: EXPERIMENTAL
Intervention: TreSPE treatment (treadmill training, stretching, respiratory, and proprioceptive exercise) twice a week for 8 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TreSPE treatment
Number of subjects: 8
Study: 19224764

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with procarbazine, lomustine, and vincristine
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Anaplastic oligodendroglial tumors with EGFR(amp)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: AOA with necrosis
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: AOA with only endothelial proliferation
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Molecular factors analyzed
Number of subjects: 368
Study: 16426083

Group type: EXPERIMENTAL
Intervention: High-dose sertraline (250-400 mg/day, mean final dose = 357 mg, SD = 60)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard sertraline (200 mg/day)
Number of subjects: 66
Study: 14568832

Group type: EXPERIMENTAL
Intervention: Er:YAG laser pretreatment plus 4% lidocaine cream
Number of subjects: 320

Group type: COMPARATOR
Intervention: Laser pretreatment plus placebo
Number of subjects: 320

Group type: COMPARATOR
Intervention: 4% lidocaine cream alone
Number of subjects: 320
Study: 11144048

Group type: EXPERIMENTAL
Intervention: Hypoinhal Dermatophagoides
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8867360

Group type: EXPERIMENTAL
Intervention: Post-operative electric field stimulation
Number of subjects: 17

Group type: COMPARATOR
Intervention: No electric field stimulation (Control)
Number of subjects: 17
Study: 1513920

Group type: EXPERIMENTAL
Intervention: 0.5 to 5 mg per day of oral haloperidol
Number of subjects: 19
Study: 6468201

Group type: EXPERIMENTAL
Intervention: 24-hour cover with metronidazole and gentamicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged use of metronidazole and gentamicin for five days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis with 24-hour cover with metronidazole and five-day therapy with mezlocillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24-hour cover with metronidazole and five-day exposure to latamoxef
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 28950157

Group type: EXPERIMENTAL
Intervention: Group-based multicomponent treatment (GMT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 158
Study: 27470620

Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Entecavir
Number of subjects: 130
Study: 24813065

Group type: EXPERIMENTAL
Intervention: L-methylfolate 15 mg/d for 60 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 22914396

Group type: EXPERIMENTAL
Intervention: Pessary therapy
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Nonsurgical therapy
Number of subjects: 446
Study: 20123872

Group type: EXPERIMENTAL
Intervention: ViziLite
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: VELscope
Number of subjects: 258
Study: 17067621

Group type: EXPERIMENTAL
Intervention: Mason-Likar (ML) 12-lead ECG
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: EASI-derived 12-lead ECG
Number of subjects: 88

Group type: COMPARATOR
Intervention: 12-lead ECG acquired in clinical practice (CP)
Number of subjects: 88
Study: 15685511

Group type: EXPERIMENTAL
Intervention: Plasma IL-6 levels
Number of subjects: 206
Study: 11887516

Group type: EXPERIMENTAL
Intervention: BrushPicks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Glide floss
Number of subjects: 63
Study: 9728982

Group type: EXPERIMENTAL
Intervention: Heparin-coated stent implantation
Number of subjects: 827

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 827
Study: 8034762

Group type: EXPERIMENTAL
Intervention: Behavioral family systems therapy (BFST)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ego-oriented individual therapy (EOIT)
Number of subjects: 22
Study: 3276642

Group type: EXPERIMENTAL
Intervention: Preoperative shampoos with chlorhexidine
Number of subjects: 151

Group type: COMPARATOR
Intervention: No shampoos, surgical preparation with chlorhexidine
Number of subjects: 151

Group type: COMPARATOR
Intervention: Shampoos with iodophor, surgical preparation with iodophor
Number of subjects: 151

Group type: COMPARATOR
Intervention: No shampoos, surgical preparation with iodophor
Number of subjects: 151
Study: 1137332

Group type: EXPERIMENTAL
Intervention: 5% glucose solution infusion (glucose group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% physiological saline solution infusion (saline group)
Number of subjects: 60
Study: 31308263

Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided transmuscular quadratus lumborum block with 30 mL ropivacaine 0.375%
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 72
Study: 29097935

Group type: EXPERIMENTAL
Intervention: Individualized contrast medium injection protocol (G1)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Standard contrast medium injection (G2) with a dose of 1.5 ml/kg
Number of subjects: 324

Group type: COMPARATOR
Intervention: Standard contrast medium injection (G2)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Both groups evaluated by two independent radiologists
Number of subjects: 324
Study: 26303805

Group type: EXPERIMENTAL
Intervention: Sublingual artemether (3 mg/kg body weight)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Intravenous quinine (loading dose of 20 mg/kg followed by 10 mg/kg every 8 h)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Sublingual artemether
Number of subjects: 182

Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 182
Study: 24604111

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A (BtX‐A) injection (200 IU) in the calf muscle of one leg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sterile normal saline injection in the other leg (control)
Number of subjects: 36
Study: 22459346

Group type: EXPERIMENTAL
Intervention: Visual Urethral Mobility Examination (VUME)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Q-Tip test
Number of subjects: 54
Study: 19173737

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 3957

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 3957

Group type: COMPARATOR
Intervention: Bevacizumab + IFN-a
Number of subjects: 3957

Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 3957
Study: 17588224

Group type: EXPERIMENTAL
Intervention: Smoking pictures
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unpleasant pictures
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pleasant pictures
Number of subjects: 22
Study: 15364166

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 2 mg
Number of subjects: 127
Study: 11584152

Group type: EXPERIMENTAL
Intervention: Divalproex sodium 500 mg three times per day for 7 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 36
Study: 9559475

Group type: EXPERIMENTAL
Intervention: Heparin-surface-modified (HSM) intraocular lenses (IOLs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unmodified poly(methyl methacrylate) (PMMA) intraocular lenses (IOLs)
Number of subjects: 100
Study: 8162671

Group type: EXPERIMENTAL
Intervention: AA-2414
Number of subjects: 39
Study: 3064527

Group type: EXPERIMENTAL
Intervention: Consecutive plasmapheresis (plasma exchanges every 2 to 3 days during a period of 2 to 3 weeks) with continuation of oral immunosuppressive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic intermittent treatment (once per week) with parallel immunosuppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 plasmaphereses followed by an i.v. cyclophosphamide bolus
Number of subjects: 0
Study: 1703611

Group type: EXPERIMENTAL
Intervention: ANP (0.1 mg i.v. as a bolus)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 124394

Group type: EXPERIMENTAL
Intervention: Ointment and tulle dressing with 1500 mg Complain in 500 ml physiological saline solution daily for three days postoperatively
Number of subjects: 95

Group type: COMPARATOR
Intervention: Perforated cellophane dressing without additional medication
Number of subjects: 95
Study: 30668833

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate catheter lock solution (SBCLS)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Normal saline catheter lock solution (NSCLS)
Number of subjects: 451
Study: 28389109

Group type: COMPARATOR
Intervention: TBI group
Number of subjects: 153
Study: 26368824

Group type: EXPERIMENTAL
Intervention: MRK Ad5 gag/pol/nef subtype B HIV‐1 preventive vaccine
Number of subjects: 465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study: 24140372

Group type: EXPERIMENTAL
Intervention: Heparin-coated foldable intraocular lens (Polylens EC‐1YH PAL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control intraocular lens (Polylens EC‐1Y PAL)
Number of subjects: 40
Study: 22028418

Group type: EXPERIMENTAL
Intervention: VA‐MEDIC‐D (pharmacist-led group SMA visits)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: VA‐MEDIC‐D
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 44
Study: 19722800

Group type: EXPERIMENTAL
Intervention: Hyaluronan gel administered subgingivally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (scaling and root planing only)
Number of subjects: 12
Study: 17369119

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 131

Group type: COMPARATOR
Intervention: 2 mg apomorphine
Number of subjects: 131
Study: 16013897

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 197
Study: 11133595

Group type: EXPERIMENTAL
Intervention: AIIA given 1 h before anesthesia (n = 19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: AIIA discontinued on the day before surgery (n = 18)
Number of subjects: 37
Study: 9753234

Group type: COMPARATOR
Intervention: Omeprazole 20 mg daily for eight weeks (group O)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for eight weeks + Rebamipide 300 mg three times a day for eight weeks (group OR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for eight weeks + Amoxicillin 1500 mg three times a day for the first two weeks (group OA)
Number of subjects: 60
Study: 7992465

Group type: EXPERIMENTAL
Intervention: Casodex (50 mg daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Orchidectomy (control)
Number of subjects: 34
Study: 3416419

Group type: EXPERIMENTAL
Intervention: Allerglobuline (10% human immunoglobulin preparation of placental origin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (10% human albumin solution)
Number of subjects: 80
Study: 29210705

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline injection (control)
Number of subjects: 20
Study: 28202842

Group type: EXPERIMENTAL
Intervention: 10 g/d of trehalose
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 34
Study: 24861098

Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity (MPA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 63
Study: 22192104

Group type: EXPERIMENTAL
Intervention: Totally tubeless PCNL (Group A)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard PCNL (Group B)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study: 20387996

Group type: EXPERIMENTAL
Intervention: 10 mg EPs 7630 tablets three times a day (30‐mg group)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: 20 mg EPs 7630 tablets three times a day (60‐mg group)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: 30 mg EPs 7630 tablets three times a day (90‐mg group)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo three times a day
Number of subjects: 406
Study: 17914002

Group type: EXPERIMENTAL
Intervention: Quality improvement interventions (education and resources for medication management or psychotherapy) for 6 to 12 months
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1248
Study: 16193893

Group type: EXPERIMENTAL
Intervention: TCR peptides/IFA
Number of subjects: 24

Group type: COMPARATOR
Intervention: TCR peptides/saline
Number of subjects: 24

Group type: COMPARATOR
Intervention: IFA alone
Number of subjects: 24
Study: 12658557

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2 h before and placebo 1 h before Nd : YAG laser capsulotomy
Number of subjects: 217

Group type: COMPARATOR
Intervention: Apraclonidine 1 h before the procedure and placebo 2 h before
Number of subjects: 217
Study: 10474124

Group type: COMPARATOR
Intervention: Lanreotide-SR (LSR) administered at individually tailored dosages (30 mg i.m. at 7-21-day intervals)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Octreotide-LAR (OC-LAR) administered at 20 mg for the first three doses and 10 or 30 mg for the last three doses at 28-day intervals
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lanreotide-SR (LSR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Octreotide-LAR (OC-LAR)
Number of subjects: 12
Study: 8556398

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) 500 mg daily
Number of subjects: 467

Group type: COMPARATOR
Intervention: Zalcitabine (ddC) 2.25 mg daily
Number of subjects: 467
Study: 1806376

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg b.i.d.
Number of subjects: 489

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 489
Study: 6614421

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 12
Study: 31759097

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Bronchial washing (BW)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: BAL
Number of subjects: 91

Group type: COMPARATOR
Intervention: BW
Number of subjects: 91
Study: 29514235

Group type: EXPERIMENTAL
Intervention: Enhanced antimicrobial prophylaxis
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Group 1 (n = 355)
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Group 2 (n = 394)
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Group 3 (n = 218)
Number of subjects: 1711

Group type: EXPERIMENTAL
Intervention: Remaining groups
Number of subjects: 1711
Study: 27435979

Group type: EXPERIMENTAL
Intervention: LY2940094 (40 mg/d)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 24216403

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (1.5‐mg/kg bolus followed by 2‐mg/kg/h infusion)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal saline infusion (placebo)
Number of subjects: 51
Study: 22252909

Group type: EXPERIMENTAL
Intervention: Venlafaxine (up to 225 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 20497980

Group type: EXPERIMENTAL
Intervention: Reduction in sugar-sweetened beverage (SSB) intake by 1 serving per day
Number of subjects: 810

Group type: EXPERIMENTAL
Intervention: Reduction in sugar intake
Number of subjects: 810

Group type: COMPARATOR
Intervention: Diet beverage consumption
Number of subjects: 810

Group type: COMPARATOR
Intervention: Caffeine intake
Number of subjects: 810
Study: 17442601

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 129
Study: 16275676

Group type: EXPERIMENTAL
Intervention: Sequential administration of paclitaxel followed by oral fluoropyrimidines (UFT/S1)
Number of subjects: 1480

Group type: COMPARATOR
Intervention: UFT/S1
Number of subjects: 1480

Group type: COMPARATOR
Intervention: S1
Number of subjects: 1480
Study: 12085075

Group type: EXPERIMENTAL
Intervention: Eye patch
Number of subjects: 37

Group type: COMPARATOR
Intervention: No eye patch
Number of subjects: 37
Study: 10451462

Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR
Number of subjects: 750

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 750
Study: 8678249

Group type: EXPERIMENTAL
Intervention: Propofol (starting with 9 mg.kg‐1 h‐1, reducing to 6 mg.kg‐1 h‐1 after 20 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5% end‐tidal)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg.kg‐1
Number of subjects: 60
Study: 1691357

Group type: EXPERIMENTAL
Intervention: Enalapril (40 mg once daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg twice daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 398483

Group type: EXPERIMENTAL
Intervention: Cefaclor (250 mg every 8 hours for 7 to 10 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Amoxycillin (250 mg every 8 hours for 7 to 10 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cefaclor and Amoxycillin
Number of subjects: 61
Study: 31782656

Group type: EXPERIMENTAL
Intervention: Guided self-help (low-intensity cognitive behaviour therapy including behavioural activation)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 70
Study: 31139365

Group type: EXPERIMENTAL
Intervention: Edutainment video
Number of subjects: 363

Group type: COMPARATOR
Intervention: Standard Operating Procedure (SOP)
Number of subjects: 363

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 363

Group type: COMPARATOR
Intervention: SOP
Number of subjects: 363